Background The novel SARS-CoV-2 has caused the coronavirus disease 2019 (COVID-19) pandemic. Currently, with insufficient worldwide vaccination rates, identifying treatment solutions to reduce the impact of the virus is urgently needed. Method An adaptive, multicentric, open-label, and randomized controlled phase I/II clinical trial entitled the “SENTAD-COVID Study” was conducted by the Abu Dhabi Stem Cells Center under exceptional conditional approval by the Emirates Institutional Review Board (IRB) for COVID-19 Research Committee from April 4th to July 31st, 2020, using an autologous peripheral blood non-hematopoietic enriched stem cell cocktail (PB-NHESC-C) administered by compressor (jet) nebulization as a complement to standard care therapy. The primary endpoints include safety and efficacy assessments, adverse events, the mortality rate within 28 days, and the time to clinical improvement as measured by a 2-point reduction on a seven-category ordinal scale or discharge from the hospital whichever occurred first. Results The study included a total of 139 randomized COVID-19 patients, with 69 in the experimental group and 70 in the control group (standard care). Overall survival was 94.20% for the cocktail-treated group vs. 90.27% for the control group. Adverse events were reported in 50 (72.46%) patients receiving PB-NHESC-C and 51 (72.85%) in the control group ( p = 0.9590), with signs and symptoms commonly found in COVID-19. After the first 9 days of the intervention, 67.3% of cocktail-treated patients recovered and were released from hospitals compared to 53.1% (RR = 0.84; 95% CI, 0.56–1.28) in the control group. Improvement, i.e., at least a 2-point reduction in the severity scale, was more frequently observed in cocktail-treated patients (42.0%) than in controls (17.0%) (RR = 0.69; 95% CI, 0.56–0.88). Conclusions Cocktail treatment improved clinical outcomes without increasing adverse events. Thus, the nebulization of PB-NHESC-C was safe and effective for treatment in most of these patients. Trial registration ClinicalTrials.gov. NCT04473170 . It was retrospectively registered on July 16th, 2020.
【저자키워드】 COVID-19, stem cells, immunomodulation, Recovery of function, Nebulizers and vaporizers, 【초록키워드】 Treatment, coronavirus disease, SARS-CoV-2, Efficacy, clinical trial, pandemic, therapy, Open-label, adaptive, severity, hospital, Intervention, complement, Symptom, virus, discharge, Peripheral blood, Clinical outcome, adverse events, improvement, Randomized, Patient, Control, Clinical improvement, mortality rate, patients, COVID-19 patients, cocktail, primary endpoint, Safe, institutional review board, reduction, Adverse, control group, 95% CI, assessments, standard care, experimental group, overall survival, Registered, approval, center, seven-category ordinal scale, vaccination rates, Administered, IRB, effective, Cell, autologous, event, STEM, Committee, Emirate, Result, occurred, caused, include, reported, conducted, receiving, reduce, reduction in, released, exceptional, Abu, 【제목키워드】 randomized clinical trial, Efficacy, Safety, Cell, autologous, Abu,